For multiple myeloma patients at first relapse,

DISCOVER DARZALEX®
(daratumumab)

DARZALEX® is a CD38-directed cytolytic antibody indicated:

  • in combination with lenalidomide and dexamethasone, or bortezomib and dexamethasone, for the treatment of patients with multiple myeloma who have received at least one prior therapy
  • in combination with pomalidomide and dexamethasone for the treatment of patients with multiple myeloma who have received at least two prior therapies including lenalidomide and a proteasome inhibitor
  • as monotherapy, for the treatment of patients with multiple myeloma who have received at least three prior lines of therapy including a proteasome inhibitor (PI) and an immunomodulatory agent or who are double-refractory to a PI and an immunomodulatory agent.

DISCOVER MORE

Pollux_Mobile_Trial_Page_Badge

DARZALEX® + Revlimid® (lenalidomide) + dexamethasone

Looking for information to help start patients on DARZALEX® therapy?

GET STARTED

DISCOVER CASTOR

Castor_Mobile_Trial_Page_Badge

DARZALEX® + Velcade® (bortezomib) + dexamethasone

Looking for information to help start patients on DARZALEX® therapy?

GET STARTED

DISCOVER SIRIUS

SIRIUS_Trial_Page_Badge

Sirius_Mobile_Trial_Page_Badge

DARZALEX® (daratumumab)

Looking for information to help start patients on DARZALEX® therapy?

GET STARTED